2. That’s a lot of aspirin

Bayer plans to unlock some of the potential within its ranks by establishing start-up-like entities. Bayer is trying the spin-out approach to developing next-gen solutions in human, animal, and agriculture technologies such as stem cells, RNA inhibition/activation, the microbiome, and DNA editing. One of the first, and probably best-funded is Casebia, a joint venture founded by Bayer and CRISPR Therapeutics. Casebia was initially funded with $300M from Bayer and another $35M was spent to give Bayer an unspecified stake in CRISPR. Casebia has access to gene-editing technology from CRISPR in specific disease areas, as well as access to protein engineering expertise and relevant disease know-how through Bayer. Prescription for success? Not sure, but take two of these and call me in the morning.

Now don't be stingy. Share this.Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn